[Dendritic cell vaccine for intrahepatic cholangio cellular carcinoma--a study of relationship between immuno-reaction and clinical outcome].
The clinical outcome of intra-hepatic cholangiocelluler carcinoma (ICC) is very poor. To prevent a tumor relapse after curative operation, we employed the combination therapy of adaptive transfer of anti-CD3 activated T cells and dendritic cell vaccine therapy (DC-CAT therapy) since 2000. During DC-CAT therapy, about a half of patient revealed skin reaction positive. Moreover, the patient who had a skin reaction showed a significantly good clinical outcome. In this study, we investigated the difference between skin reaction positive and negative checking with the surface markers of T cells. The patient who had skin reaction positive increased the number of lymphocyte. Especially, CD8 positive T cells were increased about 2 folds in number before the DC-CAT therapy, and decreased Foxp3 positive regulatory T cells. Our data suggest that increasing cytotoxic T cells and decreasing regulatory T cells made the difference of the clinical outcome such as a disease free survival rate and overall survival rate after curative operation for ICC patient.
Kotera
Yoshihito
Y
Department of Surgery, Tokyo Medical University.
Kougen
Yumi
Y
Aruga
Atsushi
A
Yamamoto
Masakazu
M
D056704:Adaptive Immunity; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000628:therapy*; D001653:Bile Ducts, Intrahepatic; D019496:Cancer Vaccines / Q000276:immunology*; D018281:Cholangiocarcinoma / Q000401:mortality / Q000628:therapy*; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
D019496:Cancer Vaccines